Navigation Links
Targeting neurotransmitter may help treat gastrointestinal conditions
Date:12/4/2012

HERSHEY, Pa. -- Selective targeting of the neurotransmitter that differentially affects brain cells that control the two distinct functions of the pancreas may allow for new medication therapies for conditions like diabetes, dyspepsia and gastro-esophageal reflux, according to Penn State College of Medicine researchers.

"This study differs from what's been reported previously about brain neurons that control the gastrointestinal tract," said R. Alberto Travagli, professor, Department of Neural and Behavioral Sciences, and lead investigator. "It provides further support to the idea that separate nerve pathways regulate the diverse functions of organs along the upper gastrointestinal tract."

The pancreas has two functional parts: one that releases digestive enzymes, and one that releases hormones like insulin and glucagon. The vagus nerve, which originates in the brain, regulates both of these pancreatic functions. This nerve detects chemical and biological changes that occur along the gastrointestinal tract and interprets and integrates these signals before sending appropriate responses back to the organs. In the brain, these signals tell the nerves controlling each specific organ what the proper response is -- for example, digestive processes and insulin release -- according to the signals detected in the GI tract.

Neurotransmitters in the brain and in organs like the pancreas control the nerve networks that receive these signals. Neurotransmitters are chemicals released from nerves that allow them to communicate with each other as well as with organs of the body. One of these neurotransmitters is glutamate, which acts on specific proteins called receptors that are present on the nerve cells. There are different classes and types of receptors that glutamate can act upon; one major class of these receptors is metabotropic glutamate receptors (mGluRs). This class is further divided into three subgroups -- I, II or III -- depending on their location
'/>"/>

Contact: Matthew Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model
2. Targeting inflammation to treat depression
3. Targeting inflammation to prevent, treat cancers
4. New targeting technology improves outcomes for patients with atrial fibrillation
5. IBN discovers human neural stem cells with tumor targeting ability
6. Scientists tailor cell surface targeting system to hit organelle ZIP codes
7. Alzheimer protein seems to slow down neurotransmitter production
8. Treating Eczema
9. How “Eczema Free Forever” Can Help People Treat Eczema Forever
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Faster Weight Loss than a "No-Diet" Weight Loss Diet
11. PET imaging used to more accurately manage treatment, predict survival for patients with gliomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Today at the State Capitol, ... with the California Healthcare Institute (CHI) and the ... Assembly resolution recognizing Feb. 28, 2015 as Rare ... caring for millions of Californians living with nearly ... policy research organization, representing leading California academic institutions, ...
(Date:3/2/2015)... 02, 2015 Surgeons at the ... Allegheny Health Network, are exploring an innovative use ... Visual Info Zonal Reminder (VIZR), to assist in the ... Google Glass is a wearable technology with an optical ... format. Wearers communicate with the Internet via natural language ...
(Date:3/2/2015)... Ticket Down is a reputable source ... . This popular site has reduced all ticket prices ... for added savings. , Parrotheads in the Los Angeles ... headlining at the Hollywood Bowl for the first time ... October 22nd and it will be in conjunction with ...
(Date:3/2/2015)... Doctors in Novara, Italy have found that ... outcomes for people with mesothelioma than other clinical factors. ... new study on the Surviving Mesothelioma website. , ... Piedmont followed the cases of 172 mesothelioma patients ... fluid. , “Persistent lung expansion after pleural talc ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service ... Standard Platinum Resistance Thermometers (SSPRTs) and industrial Resistance ... less . . . guaranteed. Their ... Code 200706-0), ISO 9001 and 17025 Certified and ... -196°C to 500°C, both ITS-90 and Callendar-van Dusen ...
Breaking Medicine News(10 mins):Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2
... Study may lead to new treatments for PTSD, researchers ... with stress-related psychiatric conditions have faulty circuitry in the ... new study suggests. , For the study, researchers presented ... patients, those with major depression and those with other ...
... and dental office,staff have realized the benefits of ... taken advantage of electronic predeterminations.,These electronic transactions may ... benefit information while the patient is still,in the ... "Paper submissions typically take 10 to 14 business ...
... starting school suffer from sleep disturbances and these may ... current edition of Deutsches rzteblatt International ( ... and adolescent psychiatrist Gerd Lehmkuhl and his colleagues present ... , The authors have as yet interviewed 1388 children ...
... , Montreal, December 3rd, 2008 A Canadian and ... from the Research Institute at the Montreal Children,s Hospital of ... Canadian Institutes of Health Research (CIHR) and the Foundation Fighting ... research project to develop innovative gene therapies for a number ...
... CINCINNATI A genetic malfunction that causes DNA instability ... put them at high risk for squamous cell carcinomas ... posted online ahead of print by Oncogene . ... report the breakdown of a cell signaling pathway for ...
... HLTH Corporation (Nasdaq: HLTH ) announced today ... 80,000,000 shares of its common stock at a price of $8.80 ... on November 25, 2008. As previously announced, HLTH exercised its ... extending the tender offer and has accepted for purchase 83,699,922 shares, ...
Cached Medicine News:Health News:Memory Formation Different in Those With Stress-Related Psychiatric Disorders 2Health News:Electronic Submission for Dental Predeterminations May Increase Efficiency, Patient Satisfaction 2Health News:CA$2.4 million toward gene therapy for human degenerative retinal diseases 2Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 2Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 3Health News:Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer 4Health News:HLTH Corporation Announces Final Results of Its Tender Offer 2Health News:HLTH Corporation Announces Final Results of Its Tender Offer 3
(Date:3/2/2015)... 2, 2015   Emerson Ecologics, LLC ... supplements, prescription products and natural health and ... with Anabolic Laboratories, a leading manufacturer of ... new partnership will allow Anabolic Laboratories to ... practitioner segments and provide customers with added ...
(Date:3/2/2015)... Conn., March 2, 2015  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... twelve months ended December 31, 2014. Fourth ... for Distribution and Reinvestment ("CAD" or "Cash Flow") of ... $58.0 million for the full year 2014;  , ...
(Date:3/2/2015)... CUPERTINO, Calif. , March 2, 2015 /PRNewswire/ ... announced its Epigenomic Regulator Program, and the successful ... the program,s lead product candidate DUR-928.  DUR-928 is ... may have broad applicability in metabolic diseases such ... steatohepatitis (NASH), and in acute organ injuries such ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 2Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 3Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 4Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 5Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 6Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 7Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 8Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 9Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 10Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 11Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 12Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 13Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 14Compass Diversified Holdings Reports Fourth Quarter and Full Year 2014 Financial Results 15DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5
... Dec. 4 Long-term data published in,EuroIntervention showed ... (MVA),after repair with the MitraClip(R) system to correct ... mitral stenosis. Additionally,with two years of follow-up, none ... surgery for mitral stenosis. At 12 months no,important ...
... newly diagnosed patients with a life-threatening type of leukemia to be ... , - Exjade results at ASH to show benefits ... damage key organs , , - ... to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen , ...
Cached Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
... Medical® clear, all-silicone Foley catheters eliminate ... other Foley catheter designs. As an ... for creating a safe, dependable Foley ... Medical's all-silicone catheters will not leach ...
... Used for stone manipulation ... tract. Enhanced wire strength permits ... ureter more readily than standard ... facilitates easy, ergonomic one-handed operation. ...
... for soft-tissue repair, including, ... paravaginal repairs, such as ... Surgisis® ES is designed ... for intraoperative applications. Supplied ...
... Used to prevent ... allow renal drainage after ... in peel-open packages. Intended ... Periodic evaluation is advised; ...
Medicine Products: